SCHEDULE: Octagon Capital Advisors Discloses 5.7% Stake in Unicycive

Octagon Capital Advisors LP and affiliated entities, along with Ting Jia, reported a combined beneficial ownership of 5.7% of Unicycive Therapeutics, Inc.'s common stock.

Summary

• Octagon Capital Advisors LP, Octagon Investments Master Fund LP, Octagon Private Opportunities Fund II LP, and Ting Jia (collectively, the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13G.
• The Reporting Persons collectively beneficially own 1,000,000 shares of Unicycive Therapeutics, Inc. common stock.
• This represents 5.7% of the issuer's outstanding common shares.
• The percentage is calculated based on 17,661,698 common shares outstanding as of August 14, 2025.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Unicycive Therapeutics, Inc.
• Octagon Capital Advisors LP serves as the investment manager for Octagon Investments Master Fund LP and Octagon Private Opportunities Fund II LP.
• Ting Jia is the managing member of Octagon Capital Advisors LP and is deemed to beneficially own the shares held by the funds.
• Octagon Investments Master Fund LP directly holds 650,000 shares, representing 3.7% of the class.
• Octagon Private Opportunities Fund II LP directly holds 350,000 shares, representing 2.0% of the class.

Sentiment

Score: 7

Explanation: The disclosure of a 5.7% beneficial ownership by a group of investment funds and their principal, Octagon Capital Advisors LP and Ting Jia, suggests a notable institutional endorsement of Unicycive Therapeutics, Inc. This indicates investor confidence in the company's prospects, even though the filing explicitly states the investment is not for control purposes.

Positives

• A significant institutional investor, Octagon Capital Advisors LP, and its affiliates, hold a 5.7% stake in Unicycive Therapeutics, Inc., indicating notable investor confidence in the company.
• The investment is stated to be in the ordinary course of business, suggesting a passive, long-term investment strategy rather than an activist play.

Risks

• The filing explicitly states that the shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating risks associated with activist investor intervention.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in Unicycive Therapeutics, Inc., a company likely operating in the biotechnology or pharmaceutical sector given its name. Such disclosures are common as investment funds adjust their portfolios and report significant ownership stakes to the SEC.

Stakeholder Impact

• Existing shareholders may view the significant institutional stake as a positive signal, potentially increasing confidence and demand for the stock.
• Company management may experience increased scrutiny or engagement from a substantial institutional investor, even if the filing states no intent to influence control.

Key Dates

Recommendation

While the disclosure of a significant institutional stake by Octagon Capital Advisors LP and its affiliates is generally a positive indicator of investor confidence, a Schedule 13G filing primarily serves as a transparency mechanism for beneficial ownership. It does not provide new operational, financial, or strategic information about Unicycive Therapeutics, Inc. that would warrant a 'buy' or 'sell' recommendation. The 'hold' recommendation reflects that this filing alone does not change the fundamental investment thesis but confirms institutional interest. Investors should continue to monitor the company's performance and other disclosures for more comprehensive investment decisions.

Keywords

Unicycive Therapeutics, Octagon Capital Advisors, Schedule 13G, beneficial ownership, institutional investment, common stock, investment management, Ting Jia